生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK1161 生物科技

午间休市 06-16 12:00:00

4,431.922

-82.258

-1.82%

最高4,537.049	最低4,397.162	成交量8,647万
今开4,512.444	昨收4,514.180	日振幅3.10%
总市值0.00	流通市值0.00	总股本0.00
成交额25.59亿	换手率--	流通股本0.00
市净率5.064023	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"BK1161","market":"HK","secType":"PLATE","nameCN":"生物科技","latestPrice":4431.9224,"timestamp":1781582399064,"preClose":4514.18,"halted":0,"volume":86472338,"delay":0,"changeRate":-0.018222,"floatShares":0,"shares":0,"eps":0,"marketStatus":"午间休市","change":-82.257813,"latestTime":"06-16 12:00:00","open":4512.444,"high":4537.049,"low":4397.162,"amount":2558542259,"amplitude":0.030988,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781586000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1781573400000,1781582400000],[1781586000000,1781596800000]],"pbRate":5.064023,"peRate":-305.909852,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1161/","defaultTab":"news","newsList":[{"id":"2643093780","title":"医美概念股普跌 三生制药(01530)下挫5.67% 机构指市场逐步由流量竞争转向品牌竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2643093780","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643093780?lang=zh_cn&edition=full","pubTime":"2026-06-16 10:25","pubTimestamp":1781576726,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医美概念股普跌，截至发稿，三生制药(01530)跌5.67%，四环医药(00460)跌4.30%，巨子生物(02367)跌2.06%，复锐医疗科技(01696)跌1.98%，山东新华制药股份(00719)跌1.91%，昊海生物科技(06826)跌1.90%。消息面上，华龙证券表示，行业层面，医美市场逐步由流量竞争转向品牌竞争，精细化运营及长期用户管理成为机构提升竞争力的重要方向。产品层面，胶原蛋白注射产品商业化落地持续推进，行业发展重心正由传统填充向组织修复、皮肤质量改善及长期抗衰升级。长期来看，具备核心研发能力及品牌运营优势的企业有望持续受益于行业高质量发展趋势。","market":"other","thumbnail":"https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983863","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1207","SG9999004311.SGD","BK1600","00460","BK1191","06826","02367","HK0000165453.HKD","BK1161","BK1515","BK1583","LU2488822045.USD","01530","01696","BK1100","00719","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643784676","title":"在成长与安全之间寻找平衡点 公私募探讨下半年科技投资大方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2643784676","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643784676?lang=zh_cn&edition=full","pubTime":"2026-06-16 07:11","pubTimestamp":1781565106,"startTime":"0","endTime":"0","summary":"【在成长与安全之间寻找平衡点 公私募探讨下半年科技投资大方向】一边是激荡的人工智能产业浪潮，以及地缘局势不确定性的缓解，令市场参与者心潮澎湃、不敢缺席；另一边却是相关个股在经历前期大幅上涨后，估值攀升至历史高位。站在当前时点，在深度认可科技主线的同时，公私募下半年如何更好地应对市场波动，并发掘新的投资机会？","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/news/11791,202606163771945955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["BK4588","BK1161","AIPO","ARTY","BK1574","BK4023","BK4551","CHAT","AI","BK4528","BK4543","BK4587","AGIX","BK4585","AIYY","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103772985","title":"云顶新耀达成重磅协议：预付款1000万美元，开发及销售里程碑总额高达3.3亿美元，外加10%-15%销售分成","url":"https://stock-news.laohu8.com/highlight/detail?id=1103772985","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103772985?lang=zh_cn&edition=full","pubTime":"2026-06-16 07:11","pubTimestamp":1781565072,"startTime":"0","endTime":"0","summary":"云顶新耀宣布达成一项具有里程碑意义的授权合作协议。根据协议条款，公司将获得一笔1000万美元的预付款，并有资格获得总额高达3.3亿美元的里程碑付款。这笔款项具体包括：高达3000万美元的开发里程碑款项，以及高达3亿美元的销售里程碑款项。此外，云顶新耀还将根据产品的全球净销售额，获得10%至15%的阶梯式特许权使用费。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK7508","BK7067","BK1161","DXB.AU","01952","BK1574","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643412781","title":"云顶新耀(01952)获Dimerix授予独家许可在大中华区、韩国及若干东南亚国家开发及商业化DMX-200","url":"https://stock-news.laohu8.com/highlight/detail?id=2643412781","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643412781?lang=zh_cn&edition=full","pubTime":"2026-06-16 06:58","pubTimestamp":1781564298,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云顶新耀 公布，于2026年6月16日，公司与Dimerix Limited订立协议，据此，Dimerix不可撤销地向公司授予一项独家许可，以在大中华区、韩国及若干东南亚国家开发及商业化DMX-200。DMX-200是一种趋化因子受体2的小分子抑制剂，目前正在进行针对局灶节段性肾小球硬化症的关键性临床3期研究ACTION3。DMX-200已获得美国食品药品监督管理局及欧洲药品管理局的孤儿药资格认定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454717.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1161","BK1574","01952","DMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643769204","title":"九源基因(02566.HK)：撤销监事会","url":"https://stock-news.laohu8.com/highlight/detail?id=2643769204","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643769204?lang=zh_cn&edition=full","pubTime":"2026-06-15 23:17","pubTimestamp":1781536625,"startTime":"0","endTime":"0","summary":"格隆汇6月15日丨九源基因(02566.HK)宣布，公司已撤销监事会，自2026年6月15日起生效。监事的职权将由董事会审核委员会行使。叶建才、徐飞虎及赵飞将不再担任公司监事，公司治理政策中有关监事及监事会的相关条文将相应废除。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260615/32280444.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02566","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643201287","title":"九源基因(02566)将于7月30日派发末期股息每10股0.57元","url":"https://stock-news.laohu8.com/highlight/detail?id=2643201287","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643201287?lang=zh_cn&edition=full","pubTime":"2026-06-15 22:34","pubTimestamp":1781534098,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因(02566)发布公告，该公司将于2026年7月30日派发末期股息每10股0.57元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454679.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02566","BK4585","BK1161","VIG","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643201293","title":"九源基因(02566)：黄文礼获选为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2643201293","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643201293?lang=zh_cn&edition=full","pubTime":"2026-06-15 22:33","pubTimestamp":1781534019,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因(02566)发布公告，黄文礼博士已于股周年大会上获选为第一届董事会独立非执行董事。黄博士的任期将直至第一届董事会任期届满为止，自2026年6月15日起生效。于2026年6月15日召开的公司职工代表大会上，徐飞虎先生获选为第一届董事会的职工代表董事。徐先生的任期将持续至第一届董事会任期届满为止。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454675.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02566","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643201239","title":"信达生物(01801)授出5000份购股权及10.52万股受限制股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2643201239","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643201239?lang=zh_cn&edition=full","pubTime":"2026-06-15 22:32","pubTimestamp":1781533949,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物(01801)发布公告，于2026年6月15日，公司根据2024年股份计划的条款向一名承授人授出5000份购股权并向22名承授人授出10.52万股受限制股份，惟须待承授人接纳。所有承授人均为本集团的非关连雇员(不属高级管理层)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454673.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828805.USD","LU2242644610.SGD","LU0455707207.USD","LU2097828557.USD","HK0000165453.HKD","BK1583","LU0502904849.HKD","LU1969619763.USD","LU2097828714.EUR","LU2328871848.SGD","LU2488822045.USD","01801","LU2097828474.EUR","BK1589","LU2097828631.EUR","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643209020","title":"基石药业-B(02616)6月15日斥资2.8万港元回购6000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2643209020","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643209020?lang=zh_cn&edition=full","pubTime":"2026-06-15 22:02","pubTimestamp":1781532164,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B(02616)发布公告，于2026年6月15日斥资2.8万港元回购6000股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02616","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643773209","title":"荃信生物-B(02509)6月15日斥资62.98万港元回购4.12万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2643773209","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643773209?lang=zh_cn&edition=full","pubTime":"2026-06-15 21:59","pubTimestamp":1781531973,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B(02509)发布公告，于2026年6月15日斥资62.98万港元回购4.12万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643065203","title":"维升药业-B(02561)6月15日斥资约29.26万港元回购1.49万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2643065203","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643065203?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:27","pubTimestamp":1781526433,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维升药业-B(02561)发布公告，于2026年6月15日该公司斥资约29.26万港元回购1.49万股，回购价格为每股19.50至19.94港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454602.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643205502","title":"执行董事唐敏捷增持昊海生物科技(06826)0.5万股 每股作价16.2港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2643205502","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643205502?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:07","pubTimestamp":1781525254,"startTime":"0","endTime":"0","summary":"香港联交所最新资料显示，6月12日，执行董事唐敏捷增持昊海生物科技(06826)0.5万股，每股作价16.2港元，总金额为8.1万港元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260615/20260615200800_32621.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260615/20260615200800_32621.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06826","EWH","BK1593","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643272595","title":"翰思艾泰-B(03378)6月15日斥资45.34万港元回购1.7万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2643272595","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643272595?lang=zh_cn&edition=full","pubTime":"2026-06-15 17:57","pubTimestamp":1781517463,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰思艾泰-B(03378)发布公告，该公司于2026年6月15日斥资45.34万港元回购1.7万股股份，每股回购价格为26-27.44港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454469.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1535","BK1173","03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643498274","title":"6月15日君实生物发生1笔大宗交易 成交金额1980万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2643498274","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643498274?lang=zh_cn&edition=full","pubTime":"2026-06-15 17:52","pubTimestamp":1781517163,"startTime":"0","endTime":"0","summary":"证券之星消息，6月15日君实生物发生大宗交易，交易数据如下：大宗交易成交价格30元，相对当日收盘价折价0.66%，成交66万股，成交金额1980万元，买方营业部为中信建投证券股份有限公司总部，卖方营业部为中信证券股份有限公司上海浦东新区东方路证券营业部。近三个月该股共发生6笔大宗交易，合计成交3.96万手，折价成交6笔。截至2026年6月15日收盘，君实生物报收于30.2元，下跌1.6%，换手率1.76%，成交量13.46万手，成交额4.07亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500023192.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1515","01877","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643274825","title":"歌礼制药-B(01672)6月15日斥资191.83万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2643274825","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643274825?lang=zh_cn&edition=full","pubTime":"2026-06-15 17:40","pubTimestamp":1781516414,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2026年6月15日，该公司斥资191.83万港元回购20万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454447.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1161","01672","BK1574","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643271774","title":"加科思-B(01167)6月15日斥资约49.71万港元回购11.16万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2643271774","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643271774?lang=zh_cn&edition=full","pubTime":"2026-06-15 17:34","pubTimestamp":1781516086,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B(01167)发布公告，于2026年6月15日该公司斥资约49.71万港元回购11.16万股，回购价格为每股4.44至4.49港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454440.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01167","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643753762","title":"海思科：公司负责礼来选定的最多五个靶点创新药项目的发现及早期研发工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2643753762","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643753762?lang=zh_cn&edition=full","pubTime":"2026-06-15 15:51","pubTimestamp":1781509872,"startTime":"0","endTime":"0","summary":"证券之星消息，海思科(002653)06月15日在投资者关系平台上答复投资者关心的问题。投资者提问：请问，海思科买礼来的品种，如何进行定价？是否需要履行评估手续？海思科回复：您好，根据公司与礼来的合作协议，公司将负责礼来选定的最多五个靶点创新药项目的发现及早期研发工作，并非公司从礼来购买品种，不涉及定价和评估，感谢您的关注。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500015564.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK0033","BK1161","BK0239","BK0188","002653","BK0028","159992","BK0077","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110086674","title":"康方生物新一代HER3 ADC药物AK138d1联合依沃西单抗：首例患者入组Ib/II期乳腺癌研究，推进\"IO2.0 + ADC2.0\"战略","url":"https://stock-news.laohu8.com/highlight/detail?id=1110086674","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110086674?lang=zh_cn&edition=full","pubTime":"2026-06-15 14:53","pubTimestamp":1781506404,"startTime":"0","endTime":"0","summary":"康方生物的新一代HER3靶向抗体偶联药物AK138d1，与依沃西单抗联合疗法的Ib/II期乳腺癌临床研究，已迎来首例患者入组。这一进展标志着公司\"免疫治疗2.0（IO2.0）与抗体偶联药物2.0（ADC2.0）\"双平台协同发展战略的实质性推进。该研究旨在评估这一创新联合疗法在HER3表达阳性晚期实体瘤，特别是乳腺癌患者中的安全性、耐受性及初步疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","LU0348766576.USD","LU0561508036.HKD","BK1574","LU1961090484.USD","LU0348767384.USD","LU1720050803.USD","09926","LU0348825331.USD","LU2476274720.SGD","LU2488822045.USD","LU2476274308.USD","LU0348735423.USD","BK1161","LU0348827113.USD","LU0348784397.USD","LU0417516902.SGD","LU0348783233.USD","LU0417516738.SGD","IE00B543WZ88.USD","LU0417516571.SGD","LU2399975544.HKD","LU0540923850.HKD","IE00BPRC5H50.USD","LU0634319403.HKD","LU2778985437.USD","LU1794554557.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643227978","title":"多家药企宣布回购增持计划，能否挽救创新药板块低迷情绪？","url":"https://stock-news.laohu8.com/highlight/detail?id=2643227978","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643227978?lang=zh_cn&edition=full","pubTime":"2026-06-15 14:03","pubTimestamp":1781503380,"startTime":"0","endTime":"0","summary":"在国内生物医药板块持续走低的背景下，多家国内创新药企宣布了回购或增持计划，向市场传递信心。　　6月15日早盘，港股龙头药企中国生物制药公告称，公司董事会决议通过一项股份购买计划，将视市场情况于未来12个月以不超过20亿港元总价在公开市场上回购本公司股份，及指示负责管理股份奖励计划的受托人购买股份。据不完全统计，这是今年以来创新药企业最大金额的回购计划。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-06-15/doc-inicnisv8303280.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-06-15/doc-inicnisv8303280.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643222786","title":"港股异动 | 科济药业-B(02171)涨超5% CT0596和CT1190B研究结果已于EHA年会上进行壁报展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2643222786","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643222786?lang=zh_cn&edition=full","pubTime":"2026-06-15 13:50","pubTimestamp":1781502601,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科济药业-B(02171)涨超5%，截至发稿，涨4.86%，报15.75港元，成交额8618.49万港元。消息面上，6月15日，科济药业-B发布公告，CT0596(一种靶向BCMA的通用型CAR-T细胞产品)用于治疗复发 ╱ 难治性多发性骨髓瘤(R/R MM)和浆细胞白血病(PCL)的研究结果，及CT1190B(一种靶向CD19/CD20的通用型CAR-T细胞产品)用于治疗复发╱难治性B细胞非霍奇金淋巴瘤(R/R B-NHL)的研究结果，已在2026年欧洲血液学协会(EHA)年会上进行壁报展示。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1161","BK4588","BK1587","BK1574","BK1585","02171","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0075},{"period":"1month","weight":-0.0431},{"period":"3month","weight":-0.0397},{"period":"6month","weight":-0.0246},{"period":"1year","weight":0.0398},{"period":"ytd","weight":-0.0307}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1161","nameEN":"BK1161"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK1161,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}